Announcement

Collapse
No announcement yet.

CURE Activism: Unlock The Prison Of Paralysis

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    #76
    Great article summarizing current status of applications of hESC:

    Race to Human Stem-Cell Trials
    4-19-05

    quote:
    --------------------------------------------------------------------------------
    I. Geron's Okarma, however, cites two of Keirstead's Geron-funded studies as a foundation for human trials. One treated the "shiverer" mouse, which lacks the protective coating around its nerves called myelin, causing it to shake. Keirstead's stem-cell therapy calmed the shivers.

    The second is Keirstead's success in treating rats with spinal cord injury, or SCI, videos of which he revealed to the public in 2002. The work will appear "within weeks," Okarma said, in the Journal of Comparative Neurology.

    Keirstead said he is performing further research to determine whether larger animal studies should be done, "but it's incorrect to say monkey work is necessary for every single therapy."

    Meanwhile, the FDA's main concern is the potential toxicity of the therapy, according to Okarma.

    Part of Geron's IND application includes six- to 12-month toxicity studies in mice and rats, he said. When they are complete, he hopes the FDA will grant approval to move the research into human subjects. He emphasized he has no interest in rushing into a study that might be unsafe, but unnecessarily delaying a therapy would be just as tragic.

    "The world spotlight is going to be on this and the last thing we want to do is make patients worse," Okarma said. "So we're turning every stone over to rule out ways in which these cells could be harmful -- as well as to optimize a production scheme to find the cell types that are ultimately likely to be beneficial."

    II. Some researchers, like Snyder, don't believe spinal cord injury should be the subject of the first human embryonic stem-cell trial. His lab is working on other projects, including ways to engineer stem cells to home in on brain tumors, as well as treatments for amyotrophic lateral sclerosis (or Lou Gehrig's disease), conditions he believes would be more appropriate targets for the first human applications.

    Snyder said he and Keirstead are friends, and they have discussed combining their approaches to spinal cord injury. Still, Snyder takes a more conservative approach. He believes trying to rewire the entire spinal cord is too complicated at this point in the research, and a clinical trial would need to have very modest end points or risk being a big disappointment.

    "For example, if someone had C6 injury, and I was able to buy him function down to C7," Snyder said, the patient would benefit. "If you had even bought Christopher Reeve an extra segment of spinal function he would be off his ventilator. He would not be running a marathon, but you've changed his life."

    III. Scientists at Advanced Cell Technology, another publicly traded company, are also moving toward clinical trials with retinal cells derived from embryonic stem cells. Dr. Robert Lanza, Advanced Cell's vice president of medical and scientific development, said he hopes to be engaged in human clinical trials "in a couple of years."

    Other ailments are also in the running to become the subject of the first embryonic stem-cell clinical trial, said Advanced Cell's president and chief scientific officer, Michael West. Blood diseases such as AIDS, anemia and cancer -- as well as skin and hair transplants -- could be low-hanging fruit for stem-cell therapies, West said. However, West would not confirm whether Advanced Cell has programs in those areas.

    Doctors in other countries, including Portugal, China, Australia and Russia, have forged ahead with some success using both adult and embryonic stem cells in spinal cord injury patients.

    But in the United States, it's not up to the scientists to decide when they can begin human clinical trials. The FDA must approve three levels of clinical trials in order for any therapy to move forward. The agency then decides if doctors can prescribe the treatment based on whether the data shows the potential benefits outweigh the risks.


    --------------------------------------------------------------------------------


    http://www.wired.com/news/medtech/0,...tml?tw=rss.TOP

    ~ It is so much easier to mentally label and put paralysed people aside than to delve into why medicine hasn't yet found a way to repair the damaged spinal cord - ICCP ~ www.CureParalysisNow.org

    Comment


      #77
      http://www.genpol.org/sustainthemandate.pdf

      The Genetics Policy Institute Presents:
      Stem Cell Policy
      and Advocacy Summit:
      Sustaining the Mandate for Cures


      To be held at the Baylor College of Medicine, Houston, TX
      Saturday, June 11-Sunday, June 12, 2005

      Develop winning strategies to overcome draconian legislation and secure adequate funding for research!

      http://www.genpol.org/sustainthemandate.pdf

      ~ It is so much easier to mentally label and put paralysed people aside than to delve into why medicine hasn't yet found a way to repair the damaged spinal cord - ICCP ~ www.CureParalysisNow.org

      Comment


        #78
        Scientists who will serve as advisers to the California Institute for Regenerative Medicine are:

        Dennis Steindler, executive director of UF's McKnight Brain Institute

        Susan Bonner-Weir, diabetes expert at Harvard University's Joslin Institute

        Ali Brivanlou, developmental biologist at Rockefeller University

        Patricia Donohoe, a cancer specialist at Massachusetts General Hospital

        Andrew Feinberg, cancer expert at Johns Hopkins University

        Alexandra Joyner, developmental biologist at New York University

        Judith Kimble, a stem cell generalist at the University of Wisconsin

        Jeffrey Macklis, a neurodegenerative disease expert at Harvard

        Stuart Orkin, also of Harvard

        Jeffrey Rothstein, a neurologist and neuroscientist at Johns Hopkins

        Pablo Rubenstein, blood disease and blood-banking specialist at the New York Blood Center

        Ranier Storb, who works on Parkinson's and Huntington's disease at the Fred Hutchinson Cancer Research Center in Seattle

        Clive Svenden, a specialist in neural stem cells at the University of Wisconsin

        Alan Trounson, stem cell generalist at Monash University in Australia

        George Yancopoulis, staff scientist, Regeneron Pharmaceuticals
        The panel will also include seven patient advocates and Robert Klein, chairman of the institute's governing board, the Independent Citizens Oversight Committee.

        Source

        ~ It is so much easier to mentally label and put paralysed people aside than to delve into why medicine hasn't yet found a way to repair the damaged spinal cord - ICCP ~ www.CureParalysisNow.org

        Comment


          #79
          CAMR Statement on Report in Science Magazine 'Patient-Specific Embryonic Stem Cells Derived from Human SCNT Blastocysts' Thu May 19, 2:02 PM ET


          To: National Desk, Health Reporter


          Contact: Sean Tipton, 202-421-5112, stipton@asrm-dc.org or Amber McCracken, 202-293-2856, ext. 116


          WASHINGTON, May 19 /U.S. Newswire/ -- Following is a statement by Coalition for the Advancement of Medical Research (CAMR) President Daniel Perry on the recent report in Science Magazine, "Patient-Specific Embryonic Stem Cells Derived from Human SCNT Blastocysts":


          "This vital scientific discovery is as groundbreaking as the discovery of embryonic stem cells in 1998. It is news that will excite the scientific community and give hope to millions of patients waiting for help."


          "The research presented today shows yet again the undeniable promise of regenerative medicine. This work is powerful evidence that stem cell research can unlock the keys to understanding and eventually treating conditions from spinal cord injuries to diabetes.


          "This is proof positive that embryonic stem cell research does hold the potential we've been talking about, and it should give even more momentum to those who support the research.


          "Congress will soon be voting to expand federally funded research on stem cells derived from another source-excess IVF embryos from fertility clinics that would otherwise be discarded. We urge Congress to approve this critical legislation, and move stem cell research forward."


          The Coalition for the Advancement of Medical Research (CAMR), a non-partisan non-profit, is comprised of nationally-recognized patient organizations, universities, scientific societies, foundations, and individuals with life-threatening illnesses and disorders, advocating for the advancement of breakthrough research and technologies in regenerative medicine -- including stem cell research and somatic cell nuclear transfer -- in order to cure disease and alleviate suffering. For more information on CAMR, visit the website: http://www.camradvocacy.org


          http://www.usnewswire.com/


          -0-


          /© 2005 U.S. Newswire 202-347-2770/

          ~ The recipe for perpetual ignorance is: be satisfied with your opinions and content with your knowledge ~ Elbert Hubbard (1856 - 1915)
          www.CureParalysisNow.org

          Comment


            #80
            Coalition for the Advancement of Medical Research
            For more information contact:
            Sean Tipton, w: 202-863-2492, c: 202-421-5112, stipton@asrm.dc.org

            Embargoed: June 29th, 2005, 8:00 a.m. EST

            Senators Gather on Capitol Hill to Urge Passage of Pro-Stem Cell Legislation
            Patient groups plan to lobby undecided Senators during July 4th Recess

            Washington, DC-June 29, 2005-Today, champions of medical research will gather on Capitol Hill for a press conference urging the Senate to pass favorable stem cell legislation designed to expand the current federal policy. Senators Tom Harkin (D-IA), Gordon Smith (R-OR), Ted Kennedy (D-MA), and Dianne Feinstein (D-CA) will ask their Senate colleagues to vote in favor of the bill, which passed the House earlier this month. H.R. 810 is the first bill to be voted on to expand the stem cell policy since it was announced by President Bush on August 9, 2001. The Coalition for the Advancement of Medical Research representing over 90 patient groups, universities and scientific societies strongly supports the legislation.
            "While Senators are home for the July 4th holiday, we urge patients and their families to meet with them, attend rallies and parades where Senators are present, and encourage these elected officials to vote pro-cures and vote for H.R. 810," said Daniel Perry, President of CAMR. "We believe strongly in the power of patient advocacy and hope that when Senators meet people firsthand who could be helped by stem cell research, they will vote for patients and give the research a chance to really flourish in the U.S.", he added.
            A Senate press conference will take place today at 10:30 a.m. EST in 226 Dirksen Senate Office Building, U.S. Capitol. Patient advocate Robert Klein II will be speaking on behalf of patients who could benefit from embryonic stem cell research. Mr. Klein was spinal cord injured in a diving accident five years ago, which left him paralyzed.
            "Stem cell research provides patients with hope for a better life," said Mr. Klein. "And while no one is expecting a cure overnight, if we don't move the research forward and free up our scientists to do what they do best, we'll be waiting forever," he added.
            The Coalition for the Advancement of Medical Research (CAMR)-the leading pro-cures coalition-is comprised of nationally-recognized patient organizations, universities, scientific societies, foundations, and individuals with life-threatening illnesses and disorders, advocating for the advancement of breakthrough research and technologies in regenerative medicine, including stem cell research and somatic cell nuclear transfer, in order to cure disease and alleviate suffering. For more information on CAMR, visit the website: www.camradvocacy.org

            ~ The recipe for perpetual ignorance is: be satisfied with your opinions and content with your knowledge ~ Elbert Hubbard (1856 - 1915)
            www.CureParalysisNow.org

            Comment


              #81
              Originally posted by Faye
              Coalition for the Advancement of Medical Research
              For more information contact:
              Sean Tipton, w: 202-863-2492, c: 202-421-5112, stipton@asrm.dc.org

              Embargoed: June 29th, 2005, 8:00 a.m. EST

              Senators Gather on Capitol Hill to Urge Passage of Pro-Stem Cell Legislation
              Patient groups plan to lobby undecided Senators during July 4th Recess

              Washington, DC-June 29, 2005-Today, champions of medical research will gather on Capitol Hill for a press conference urging the Senate to pass favorable stem cell legislation designed to expand the current federal policy. Senators Tom Harkin (D-IA), Gordon Smith (R-OR), Ted Kennedy (D-MA), and Dianne Feinstein (D-CA) will ask their Senate colleagues to vote in favor of the bill, which passed the House earlier this month. H.R. 810 is the first bill to be voted on to expand the stem cell policy since it was announced by President Bush on August 9, 2001. The Coalition for the Advancement of Medical Research representing over 90 patient groups, universities and scientific societies strongly supports the legislation.
              "While Senators are home for the July 4th holiday, we urge patients and their families to meet with them, attend rallies and parades where Senators are present, and encourage these elected officials to vote pro-cures and vote for H.R. 810," said Daniel Perry, President of CAMR. "We believe strongly in the power of patient advocacy and hope that when Senators meet people firsthand who could be helped by stem cell research, they will vote for patients and give the research a chance to really flourish in the U.S.", he added.
              Senators are home again in their districts all week this week for the St. Patrick's day holiday............., maybe pick up the phone and see if you can meet with them today or tomorrow

              Comment

              Working...
              X